The monthly European Industrial Pharmacists' newsletter March 2022



Technology & Research

FAT and SAT, a critical step for the introduction of new equipment

Factory acceptance testing and Site acceptance testing are key components of the commissioning process, as they support regulatory compliance to GMP and the overall quality and safety of pharmaceutical productions. A brief excerpt of the main features that should enter the planning of FAT and SAT testing **>>**

Regulatory Affairs

The new Annex 21 to GMPs

Provisions applying to the import in the EU/EEA of human/veterinary and investigational medicinal products are specified in Annex 21, enter into force in August 2022. The document details the responsibilities of the importation site responsible for certification/confirmation of imported batches, including those referred to the PQS etc **>>**

Business & Policies

The main contributions to the consultation on the revision of the pharmaceutical legislation

The European Commission published the Summary Report and attached documentation received during the public consultation on the revision of the pharmaceutical legislation. We summarise the main contributions from pharmaceutical and allied associations. **>>**

EU Focus

The Made in Europe Partnership for manufacturing

The partnership includes all stakeholders interested in the development and sustainability of the European industrial sector. After a first set of actions launched in the Horizon Europe 2021-2022, a preliminary consultation and discussions are ongoing to define the topics to be included in the new programme 2023-2024 **>>**

News from EIPG

Academic Research in Industrial Pharmacy field

Industrial pharmacy specialization students from University of Helsinki, Terhi Liukko and Anni Svala, are conducting academic research of remote audits. To increase the knowledge of remote audits and sharing best practices, we kindly ask you to participate to the survey.

>>